Acquisitions (Tables)

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of purchase price allocation

The following table summarizes the consideration paid for the BioPhero acquisition and the amounts of the assets acquired and liabilities assumed as of the acquisition date, which have been allocated on a preliminary basis.

Preliminary Purchase Price Allocation as of July 19, 2022
(in Millions)
Fair Value of Assets Acquired
Cash	$	10.0
Intangible assets
Developed Technology (1)	66.3
In-process research & development	10.5
Goodwill	130.7
Other Assets	3.4
Total Assets	$	220.9
Fair Value of Liabilities Assumed
Deferred income tax liabilities	$	16.6
Other Liabilities	1.1
Total Liabilities	17.7
Net Assets	$	203.2
Total Purchase Consideration:	Amount
Cash purchase price, net of acquired cash	$	193.2
Cash payment from working capital adjustment (2)	2.5
Cash purchase price paid during the third quarter 2022	$	190.7
____________________
(1) Expected life is 15 years and will be amortized based on the pattern of economic benefit
(2) Payment made October 3, 2022